PTC Therapeutics
PTCT
61 hedge funds and large institutions have $297M invested in PTC Therapeutics in 2013 Q3 according to their latest regulatory filings, with 59 funds opening new positions, increasing their positions, 2 reducing their positions, and 1 closing their positions.
8,460% more capital invested
Capital invested by funds: $3.47M → $297M (+$294M)
5,800% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 1
1,933% more funds holding
Funds holding: 3 → 61 (+58)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$40.6M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$39.2M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$29.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.3M |
| 5 |
DM
Deerfield Management
New York
|
+$14.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
-$1.93M |
| 2 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$497K |
| 3 |
ICAP
Independence Capital Asset Partners
Denver,
Colorado
|
-$156K |
PTCT Hedge Fund Activity: Q3 2013 in Review
61 of the 3,096 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2013, worth a combined $297M — up 8,460% from $3.47M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new PTCT positions and 1 closed out — a net gain of 58 holders — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Bain Capital Public Equity Management, opening a new position worth an estimated $40.6M. The largest seller was Alyeska Investment Group, cutting an estimated $1.93M.
- 61 institutional investors held PTC Therapeutics (PTCT) as of Q3 2013, up from 3 in Q2 2013.
- Funds reported $297M of PTC Therapeutics stock for Q3 2013, up 8,460% quarter-over-quarter.
- 59 funds opened new PTC Therapeutics positions in Q3 2013 and 1 closed out, a net change of +58 holders.
- The largest PTC Therapeutics buyer in Q3 2013 was Bain Capital Public Equity Management, an estimated $40.6M added.
- The largest PTC Therapeutics seller in Q3 2013 was Alyeska Investment Group, an estimated $1.93M sold.
Based on aggregated 13F filings for Q3 2013.